GLP1R and myocardial infarction: A sufficient power (> 80%) to detect significant differences, as they occurred in individual trials between active drug and placebo treatment, with respect to (non-fatal) myocardial infarction was estimated in 2 out of 4 SGLT-2 I studies, in none of the DPP-4 I trials, and in 4 out of 8 GLP-1 RA studies (Fig. 2).